Prevention and treatment of infectious and inflammatory complications in gynecological patients in the postoperative period

Introduction. Currently, there is a high frequency of vaginal microbiocenosis disorders (85–90%) in the postoperative period in patients with various nosological forms of gynecological diseases requiring surgical treatment. Aim. To study the efficacy and tolerability of Depantol®, a combination of an antiseptic and a reparant complex, for the prevention and treatment of postoperative infectious and inflammatory complications of the lower genital tract after surgical interventions performed through vaginal access. Materials and methods. A prospective comparative study involving 588 patients who underwent vaginal surgery was designed to evaluate the efficacy of Depantol® in the prevention and treatment of infectious and inflammatory complications of the lower genital tract. The first group consisted of 98 patients who underwent vaginal hysterectomy, vaginal wall plastic surgery and/or transsacrospinal hysteropexy and standard postoperative management; the second group consisted of 236 patients who underwent vaginal hysterectomy and vaginal wall plastic surgery; in addition to standard therapy for 10 days, the patients received Depantol® 1 suppository 2 times a day for 10 days; the third – 254 patients after transsacrospinal hysteropexy, who received Depantol in the postoperative period, according to the instructions for use. Results. The results of the study demonstrated that clinical symptoms 14 days after treatment were observed in 49.9% of patients in the first group, 2.1% in the second, and 1.5% in the third, which may indicate a favorable effect of Depantol on the processes of trophism and regeneration of vaginal tissues, which is confirmed by 25% (OR 0.3 (CI: 0.11–0.71, p < 0.05), RR 0.25 (CI: 0.14–0.46, p < 0.05)) less pronounced hyperemia of the postoperative wound in patients of the second and third groups than in patients of the first group. Conclusions. The long-term results of the study allow us to recommend Depantol, with high compliance, good tolerability, a favorable safety profile, corresponding to the principles of FTS-active management of the postoperative period in patients after vaginal surgeries, in order to accelerate recovery by optimizing rehabilitation, reducing microbial contamination of the vagina, and enhancing the epithelialization processes of the postoperative wound.